Last reviewed · How we verify
NCT06562920: Neoadjuvant
Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
Phase 2 trial testing adebrelimab and chemotherapy in Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer in 20 participants. Currently enrolling.
31 July 2027
Quick facts
| Lead sponsor | Zhejiang Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 24 July 2024 |
| Primary completion | 31 July 2027 |
| Estimated completion | 31 July 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- adebrelimab and chemotherapy — full drug profile →
Conditions studied
- Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer — all drugs for Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer →
Sponsor
Zhejiang Cancer Hospital
Who can join
Adults 18 to 75, any sex, with Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore the effectiveness and safety of adebrelimab combined with chemotherapy and concurrent SBRT for 3 cycles of neoadjuvant treatment followed by surgery in T1-3N0-1M0 limited-stage SCLC
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06562920
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Zhejiang Cancer Hospital trials
Trials by the same sponsor.
- NCT07343479 — Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases · Phase 2 · not yet recruiting
- NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
- NCT07416890 — Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref · Phase 2 · recruiting
- NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
- NCT07330544 — A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Rec · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06562920 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang Cancer Hospital
- Last refreshed: 20 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06562920.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing